Showing results (61-70 of 580) with videos related to

Sort By:
Pageof 58
Nanoscale|May 14, 2015
Design and assembly of supramolecular dual-modality nanoprobesShuang Liu, Pengcheng Zhang, Sangeeta Ray Banerjee, et al.
Nuklearmedizin. Nuclear Medicine|January 14, 2022
[18F]DCFPyL PET/CT for Imaging of Prostate CancerSteven P Rowe, Andreas Buck, Ralph A Bundschuh, et al.
Radiologic Clinics of North America|November 16, 2023
Prostate-Specific Membrane Antigen-Ligand Therapy: What the Radiologist Needs to KnowSteven P Rowe, Mohammad S Sadaghiani, Andrei Gafita, et al.
Molecular Imaging and Biology|November 9, 2018
Impact of Tumor Burden on Quantitative [68Ga] DOTATOC BiodistributionRudolf A Werner, Heribert Hänscheid, Jeffrey P Leal, et al.
Clinical Nuclear Medicine|May 11, 2023
Impact of CXCR4-Directed PET/CT on Staging and Proposed Oncologic Management in Patients With Digestive System TumorsAlexander Weich, Sebastian E Serfling, Wiebke Schlötelburg, et al.
Nuklearmedizin. Nuclear Medicine|August 17, 2022
Clinical Utility of C-Reactive Protein and White Blood Cell Count for Scheduling an [18F]FDG PET/CT in Patients with Giant Cell ArteritisKonstanze V Guggenberger, Marius L Vogt, Steven P Rowe, et al.
Seminars in Nuclear Medicine|November 18, 2023
A Practical Guide to the Pearls and Pitfalls of PSMA PET ImagingAndrew F Voter, Rudolf A Werner, Hatice Savas, et al.
Theranostics|April 26, 2021
Current and future perspectives on functional molecular imaging in nephro-urology: theranostics on the horizonYoshitaka Toyama, Rudolf A Werner, Camilo A Ruiz-Bedoya, et al.
Nanoscale|September 12, 2022
PSMA-specific degradable dextran for multiplexed immunotargeted siRNA therapeutics against prostate cancerZhihang Chen, Balaji Krishnamachary, Yelena Mironchik, et al.
Oncotarget|December 31, 2011
A modular strategy to prepare multivalent inhibitors of prostate-specific membrane antigen (PSMA)Sangeeta Ray Banerjee, Mrudula Pullambhatla, Hassan Shallal, et al.
Pageof 58